Multi-omics Characterization of Pancreatic Neuroendocrine Tumors and Carcinomas

• Conditions: Cancer of Pancreas

• Registration Number: NCT05234450
• Lead Sponsor: University Hospital, Strasbourg, France

Brief Summary

In this work, the investigators count through the integrated multi-omics analysis to identify different tumor subgroups in pancreatic neuroendocrine tumors and carcinomas regardless of their grade and stage. To achieve this, they will resort to the use of next-generation sequencing approaches (RNAseq, then use of MCP Counter for the absolute quantification of the eight populations of immune cells in the tumor microenvironment), alterations in epigenetics with study of the methylome by MeDIP, ChIPseq, telomere (ALT) study, as well as correlation with peripheral blood neutrophil to lymphocyte ratio and immunohistochemistry data such as Ki67, p53, Rb, DAXX, ATRX, PDL1, immune cell labeling. This will be done on frozen or paraffin material. This work will provide a more complete biological picture of pancreatic neuroendocrine tumors and carcinomas.

Detailed Description

Not available

Study Timeline

• Study Start: 2021-12-01
• Status Verified: 2022-01
• Study First Submitted: 2022-01-31
• Study First Submitted QC: 2022-01-31
• Last Update Submitted: 2022-01-31
• Study First Posted: 2022-02-10
• Last Update Posted: 2022-02-10
• Primary Completion: 2022-06
• Study Completion: 2022-06-30

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 300

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Establishment of the number of tumor subgroups by integrating data from all multi-omics analyses	1 month

Trial Locations

Locations (1)

Service d'Oncologie - CHU de Strasbourg - France; 🇫🇷 Strasbourg, France